# An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies

Source: https://onco.cc/trials/nct07668453/  
OnCo record `nct07668453` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab, gemcitabine and nab-paclitaxel in gallbladder cancer and other biliary tract cancers, run by The First Affiliated Hospital with Nanjing Medical University, now recruiting.

## Summary

An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies is a phase 2 interventional study registered as NCT07668453 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 30 participants, started 2025-10-20 and due to reach its primary completion in 2027-06-30. Interventions recorded: Adebrelimab, gemcitabine, Albumin-Bound Paclitaxel /nab-Paclitaxel. Conditions listed: Biliary Tract Neoplasms. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT07668453
- Phase: 2
- Setting: An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies
- Sponsor: The First Affiliated Hospital with Nanjing Medical University
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07668453: https://clinicaltrials.gov/study/NCT07668453

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct07668453.json